Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Cyclin-dependent kinases (CDKs) regulate cell cycle progression. Certain CDKs (e.g., CDK7, CDK9) also control cellular transcription. Consequently, CDKs represent attractive targets for anticancer drug development, as their aberrant expression is common in diverse malignancies, and CDK inhibition can trigger apoptosis. CDK inhibition may be particularly successful in hematologic malignancies, which are more sensitive to inhibition of cell cycling and apoptosis induction. AREAS COVERED: A number of CDK inhibitors, ranging from pan-CDK inhibitors such as flavopiridol (alvocidib) to highly selective inhibitors of specific CDKs (e.g., CDK4/6), such as PD0332991, that are currently in various phases of development, are profiled in this review. Flavopiridol induces cell cycle arrest, and globally represses transcription via CDK9 inhibition. The latter may represent its major mechanism of action via down-regulation of multiple short-lived proteins. In early phase trials, flavopiridol has shown encouraging efficacy across a wide spectrum of hematologic malignancies. Early results with dinaciclib and PD0332991 also appear promising. EXPERT OPINION: In general, the antitumor efficacy of CDK inhibitor monotherapy is modest, and rational combinations are being explored, including those involving other targeted agents. While selective CDK4/6 inhibition might be effective against certain malignancies, broad-spectrum CDK inhibition will likely be required for most cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 5×
“, INK4 binding to cyclin D-dependent CDKs) all occur frequently in human malignancies due to chromosomal translocations, genetic mutations or by epigenetic mechanisms [1,2,6].”
BackgroundInfluentialFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 3×
“Of note, such a strategy would be expected to succeed only in cells with intact Rb function, and indeed, this has proved to be true in the case of PD0332991, a highly selective CDK4/6 inhibitor (discussed further in the following sections) [25].”
BackgroundATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks
Jazayeri, A., Falck, J., Lukas, C., Bartek, J., Smith, G. C. M., Lukas, J., & Jackson, S. P. (2006) · Nature Cell Biology · doi:10.1038/ncb1337 · Cited by 1,064
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1
Ira, G., Pellicioli, A., Balijja, A., Wang, X., Fiorani, S., Carotenuto, W., Liberi, G., Bressan, D., Wan, L., Hollingsworth, N. M., et al. (2004) · Nature · doi:10.1038/nature02964 · Cited by 722 · cited 1×
“CDK1, the only CDK that is essential for mammalian cell cycle progression in that mouse embryos lacking all interphase CDKs (CDK2, CDK3, CDK4 and CDK6) undergo organogenesis and develop to midgestation [33], is required for DNA doublestrand break (DSB) end resection, homologous recombination (HR) and DNA damage checkp…”
BackgroundSelective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388298 · Cited by 299 · cited 13×
“Very similar findings have been reported in MCL cells [111].”
BackgroundInfluentialMultiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy
Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs002 · Cited by 255
Baughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1098 · Cited by 225 · cited 1×
“Acting in concert with the endogenous CKI p18, PD0332991 potently induces G1 arrest, but not apoptosis, in primary bone marrow MM cells ex vivo and prevents tumor growth in disseminated human MM xenografts [75].”
BackgroundWang, L., Wang, J., Blaser, B. W., Duchemin, A.-M., Kusewitt, D. F., Liu, T., Caligiuri, M. A., & Briesewitz, R. (2007) · Blood · doi:10.1182/blood-2007-02-071266 · Cited by 134 · cited 1×
“In AML cell lines bearing the FLT3 internal tandem duplication (ITD) mutation, PD0332991 caused sustained cell cycle arrest and prolonged survival in an in vivo model of FLT3-ITD AML [78].”
BackgroundHuang, X., Di Liberto, M., Jayabalan, D., Liang, J., Ely, S., Bretz, J., Shaffer, A. L., Louie, T., Chen, I., Randolph, S., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415984 · Cited by 102
Cited by
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Natural product and natural product derived drugs in clinical trials
Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014) · Nat. Prod. Rep. · doi:10.1039/c4np00064a · Cited by 602
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells
Reichel, J., Chadburn, A., Rubinstein, P. G., Giulino-Roth, L., Tam, W., Liu, Y., Gaiolla, R., Eng, K., Brody, J., Inghirami, G., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610436 · Cited by 337
Pathways and mechanisms of venetoclax resistance
Bose, P., Gandhi, V., & Konopleva, M. (2017) · Leukemia & Lymphoma · doi:10.1080/10428194.2017.1283032 · Cited by 302
Self-citation
Metadata
- Authors
- Bose, P., Simmons, G. L., & Grant, S.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2013-05-06
- Volume
- 22
- Issue
- 6
- Pages
- 723-738
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2131017274
- Cited by
- 153
- References
- 12
- FWCI
- 10.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. https://app.cochat.ai/papers/10.1517/13543784.2013.789859
- The paper
- Bose, P., Simmons, G. L., & Grant, S. (2013). Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.2013.789859
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.